<DOC>
	<DOC>NCT01858363</DOC>
	<brief_summary>This is a prospective, randomized, multi-center, single-blind study to demonstrate the safety and effectiveness of the CVI Paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon versus bare PTA balloon for the treatment of patients with de novo occluded/stenotic or reoccluded/restenotic lesions of the superficial femoral (SFA) and popliteal arteries.</brief_summary>
	<brief_title>CVI Drug Coated Balloon European Randomized Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Symptomatic leg ischemia requiring treatment of the superficial femoral or popliteal arteries Rutherford clinical category 2, 3 or 4 Male or nonpregnant female at least 18 years Coexisting clinically significant aneurismal disease of the abdominal aorta, iliac or popliteal arteries Significant gastrointestinal bleeding or any coagulopathy that would contraindicate the use of antiplatelet therapy Known intolerance of study medications, paclitaxel or contrast agent Active participation in another investigational device or drug study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Peripheral arterial disease</keyword>
	<keyword>claudication</keyword>
	<keyword>drug-coated balloon</keyword>
	<keyword>drug-eluting balloon</keyword>
</DOC>